300233 金城医药
已收盘 07-17 15:00:00
资讯
新帖
简况
金城医药(300233)股东淄博金城实业投资股份有限公司质押12.75万股,占总股本0.03%
证券之星 · 07-15 21:26
金城医药(300233)股东淄博金城实业投资股份有限公司质押12.75万股,占总股本0.03%
金城医药(300233.SZ)实控人之一赵鸿富拟减持不超0.79%股份
智通财经 · 07-12
金城医药(300233.SZ)实控人之一赵鸿富拟减持不超0.79%股份
金城医药:公司烟碱销售情况良好,呈增长态势
证券之星 · 07-11
金城医药:公司烟碱销售情况良好,呈增长态势
金城医药最新公告:注射用头孢哌酮钠舒巴坦钠收到药品补充申请批准通知书
证券之星 · 07-10
金城医药最新公告:注射用头孢哌酮钠舒巴坦钠收到药品补充申请批准通知书
金城医药(300233.SZ):注射用氯诺昔康获得药品注册证书
智通财经 · 07-05
金城医药(300233.SZ):注射用氯诺昔康获得药品注册证书
金城医药(300233.SZ)子公司金城泰尔收到药品GMP符合性检查结果
智通财经 · 06-21
金城医药(300233.SZ)子公司金城泰尔收到药品GMP符合性检查结果
金城医药最新公告:子公司药品通过药品GMP符合性检查
证券之星 · 06-21
金城医药最新公告:子公司药品通过药品GMP符合性检查
金城医药:6月19日接受机构调研,西南证券、申万菱信等多家机构参与
证券之星 · 06-19
金城医药:6月19日接受机构调研,西南证券、申万菱信等多家机构参与
金城医药:中信证券、逸原达投资等多家机构于6月13日调研我司
证券之星 · 06-13
金城医药:中信证券、逸原达投资等多家机构于6月13日调研我司
禽流感概念盘中拉升,金城医药涨3.07%
自选股智能写手 · 06-12
禽流感概念盘中拉升,金城医药涨3.07%
金城医药:招商证券投资者于6月11日调研我司
证券之星 · 06-12
金城医药:招商证券投资者于6月11日调研我司
金城医药:目前尚未上市销售,公司将根据市场及客户需求安排销售事宜
证券之星 · 06-08
金城医药:目前尚未上市销售,公司将根据市场及客户需求安排销售事宜
金城医药:具体服用请按照说明书用法用量或寻求专业人士指导
证券之星 · 06-07
金城医药:具体服用请按照说明书用法用量或寻求专业人士指导
金城医药:截至2024年5月底,公司股东户数为29,813户
证券之星 · 06-07
金城医药:截至2024年5月底,公司股东户数为29,813户
金城医药最新公告:头孢羟氨苄干混悬剂增加规格取得药品补充申请批准通知书
证券之星 · 05-16
金城医药最新公告:头孢羟氨苄干混悬剂增加规格取得药品补充申请批准通知书
金城医药(300233.SZ)子公司收到氯诺昔康化学原料药上市申请批准
智通财经 · 05-14
金城医药(300233.SZ)子公司收到氯诺昔康化学原料药上市申请批准
金城医药最新公告:氯诺昔康收到化学原料药上市申请批准通知书
证券之星 · 05-14
金城医药最新公告:氯诺昔康收到化学原料药上市申请批准通知书
金城医药:公司拥有生物合成的研发及产业化平台,具备从研发到中试再到产业化落地的产业链平台优势
证券之星 · 05-10
金城医药:公司拥有生物合成的研发及产业化平台,具备从研发到中试再到产业化落地的产业链平台优势
金城医药(300233)5月7日主力资金净卖出66.44万元
证券之星 · 05-08
金城医药(300233)5月7日主力资金净卖出66.44万元
顶层文件出台在即!合成生物概念异军突起,产业发展步伐加快
格隆汇 · 05-06
顶层文件出台在即!合成生物概念异军突起,产业发展步伐加快
公司概况
公司名称:
山东金城医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2011-06-22
主营业务:
山东金城医药集团股份有限公司主要从事医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。主要产品包括AE活性酯、头孢他啶活性酯、呋喃铵盐、头孢克肟活性酯、头孢地尼活性酯以及三嗪环、头孢唑林钠、头孢曲松钠、头孢他啶、头孢噻肟、头孢硫脒、谷胱甘肽、腺苷蛋氨酸、硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、富马酸比索洛尔胶囊、氯喹那多普罗雌烯阴道片等。公司坚持医药化工和特色原料药的发展方向,经过十多年的发展,已经成为全国最大的头孢类医药中间体生产企业。
发行价格:
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":14.25,"timestamp":1721199795000,"preClose":14.2,"halted":0,"volume":2771500,"delay":0,"floatShares":370000000,"shares":384000000,"eps":0.5407,"marketStatus":"已收盘","marketStatusCode":5,"change":0.05,"latestTime":"07-17 15:00:00","open":14.2,"high":14.36,"low":14.08,"amount":39446100,"amplitude":0.0197,"askPrice":14.26,"askSize":77,"bidPrice":14.25,"bidSize":71,"shortable":0,"etf":0,"ttmEps":0.5407,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"adjPreClose":14.2,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":15.62,"lowLimit":12.78,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"pbRate":1.46,"roa":"--","roe":"2.22%","epsLYR":0.45,"committee":-0.038462,"marketValue":5470000000,"floatMarketCap":5275000000,"peRate":26.354724,"changeRate":0.0035,"turnoverRate":0.0075,"status":0},"requestUrl":"/m/hq/s/300233/wiki","defaultTab":"wiki","newsList":[{"id":"2451973640","title":"金城医药(300233)股东淄博金城实业投资股份有限公司质押12.75万股,占总股本0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451973640","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451973640?lang=zh_cn&edition=full","pubTime":"2024-07-15 21:26","pubTimestamp":1721049964,"startTime":"0","endTime":"0","summary":"证券之星消息,金城医药7月15日公开信息显示,股东淄博金城实业投资股份有限公司向海通证券股份有限公司合计质押12.75万股,占总股本0.03%。质押详情见下表:截止本公告日,股东淄博金城实业投资股份有限公司已累计质押股份3368.39万股,占其持股总数的42.88%。金城医药主营业务:涵盖医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500031195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"gpt_icon":0},{"id":"2450385215","title":"金城医药(300233.SZ)实控人之一赵鸿富拟减持不超0.79%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2450385215","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450385215?lang=zh_cn&edition=full","pubTime":"2024-07-12 21:10","pubTimestamp":1720789814,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金城医药(300233.SZ)发布公告,公司实际控制人之一赵鸿富计划在本公告披露之日起15个交易日后的3个月内以集中竞价、大宗交易方式减持公司股份不超过300万股,不超过剔除公司回购专用账户股份后总股本的0.79%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2450334731","title":"金城医药:公司烟碱销售情况良好,呈增长态势","url":"https://stock-news.laohu8.com/highlight/detail?id=2450334731","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450334731?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:04","pubTimestamp":1720692295,"startTime":"0","endTime":"0","summary":"证券之星消息,金城医药07月11日在投资者关系平台上答复投资者关心的问题。请问贵公司5月份烟碱产品的生产和销售情况如何?谢谢金城医药董秘:投资者,您好,截至2024年7月10日公司股东户数为28,351户。如有需披露的信息,我们将及时予以公告。2季度已经结束了,烟碱产品在2季度的销售和产量分别是多少呢?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100035400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2450321813","title":"金城医药最新公告:注射用头孢哌酮钠舒巴坦钠收到药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2450321813","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450321813?lang=zh_cn&edition=full","pubTime":"2024-07-10 21:49","pubTimestamp":1720619385,"startTime":"0","endTime":"0","summary":"金城医药公告,控股子公司广东金城金素制药有限公司于近日收到国家药品监督管理局下发的注射用头孢哌酮钠舒巴坦钠《药品补充申请批准通知书》。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000046982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2449261066","title":"金城医药(300233.SZ):注射用氯诺昔康获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449261066","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449261066?lang=zh_cn&edition=full","pubTime":"2024-07-05 20:29","pubTimestamp":1720182570,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金城医药(300233.SZ)公告,公司之全资子公司北京金城泰尔制药有限公司(简称“金城泰尔”)收到国家药品监督管理局下发的注射用氯诺昔康药品注册证书(证书编号:2024S01517)。注射用氯诺昔康按照化学药品4类注册申报,获批后视同通过仿制药质量和疗效一致性评价。经国家药品监督管理局网站查询,目前国内氯诺昔康的相关剂型为注射剂、片剂,在临床上主要用于手术后急性中度疼痛的短期治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2445754108","title":"金城医药(300233.SZ)子公司金城泰尔收到药品GMP符合性检查结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2445754108","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445754108?lang=zh_cn&edition=full","pubTime":"2024-06-21 20:51","pubTimestamp":1718974262,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金城医药(300233.SZ)公告,公司全资子公司北京金城泰尔制药有限公司(简称“金城泰尔”)于近日收到北京市药品监督管理局下发的《药品GMP符合性检查告知书》,其申报的磷酸奥司他韦原料药生产线、普罗雌烯原料药生产线已通过《药品生产质量管理规范》符合性检查。公告显示,磷酸奥司他韦是其活性代谢产物(奥司他韦羧酸盐)的前体药物,奥司他韦羧酸盐是选择性的流感病毒神经氨酸酶抑制剂。目前国内磷酸奥司他韦的相关剂型为胶囊、颗粒剂和干混悬剂,临床上主要适用于成人、1岁及1岁以上儿童的甲型和乙型流感治疗,成人、13岁及13岁以上青少年的甲型和乙型流感的预防。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2445549537","title":"金城医药最新公告:子公司药品通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2445549537","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445549537?lang=zh_cn&edition=full","pubTime":"2024-06-21 20:40","pubTimestamp":1718973643,"startTime":"0","endTime":"0","summary":"金城医药公告,全资子公司金城泰尔的磷酸奥司他韦和普罗雌烯原料药生产线通过药品GMP符合性检查。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100048931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2444644045","title":"金城医药:6月19日接受机构调研,西南证券、申万菱信等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2444644045","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444644045?lang=zh_cn&edition=full","pubTime":"2024-06-19 16:23","pubTimestamp":1718785408,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月19日金城医药发布公告称公司于2024年6月19日接受机构调研,西南证券杨天笑、申万菱信强泽平、观富资产杨洁、亚太资管王婷参与。金城医药主营业务:涵盖医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售等。金城医药2024年一季报显示,公司主营收入9.32亿元,同比上升12.32%;归母净利润8297.13万元,同比上升65.43%;扣非净利润8031.36万元,同比上升87.19%;负债率35.28%,投资收益-16.43万元,财务费用-54.16万元,毛利率44.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900032440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600369","BK0276","BK0239","300233","BK0183","BK0028","BK0012","BK0188"],"gpt_icon":0},{"id":"2443457402","title":"金城医药:中信证券、逸原达投资等多家机构于6月13日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2443457402","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443457402?lang=zh_cn&edition=full","pubTime":"2024-06-13 17:03","pubTimestamp":1718269383,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月13日金城医药发布公告称中信证券王凯旋、逸原达投资马淑霞于2024年6月13日调研我司。金城医药主营业务:涵盖医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售等。金城医药2024年一季报显示,公司主营收入9.32亿元,同比上升12.32%;归母净利润8297.13万元,同比上升65.43%;扣非净利润8031.36万元,同比上升87.19%;负债率35.28%,投资收益-16.43万元,财务费用-54.16万元,毛利率44.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300032612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0012","300233","BK0028","LU1794554557.SGD","BK0239","BK1521","LU1328615791.USD","BK0196","BK1147","06030","LU1720050803.USD","LU1064131003.USD","LU1997245177.USD","BK0188","LU0405327494.USD","BK1564","LU1997245094.SGD","600030","LU2148510915.USD","LU0405327148.USD","LU1064130708.USD","BK0276","BK1516"],"gpt_icon":0},{"id":"2442372736","title":"禽流感概念盘中拉升,金城医药涨3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442372736","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442372736?lang=zh_cn&edition=full","pubTime":"2024-06-12 11:05","pubTimestamp":1718161512,"startTime":"0","endTime":"0","summary":"06月12日,禽流感概念盘中拉升,截至11点05分,禽流感概念整体指数上涨1.04%,报1140.040点。从个股上来看,该概念的成分股中,金城医药涨3.07%,鲁抗医药、香雪制药、太龙药业涨幅居前。从资金上来看,截止发稿,禽流感概念主力净流入为-2886.75万,其中鲁抗医药受到资金热捧,主力净流入2005.72万;拉长时间线来看,该板块近20日主力资金净流入-49.21亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612110512af8d14d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612110512af8d14d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0046","300233","600789","BK0239","BK0188","BK0028","BK0168"],"gpt_icon":0},{"id":"2442314027","title":"金城医药:招商证券投资者于6月11日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2442314027","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442314027?lang=zh_cn&edition=full","pubTime":"2024-06-12 00:24","pubTimestamp":1718123074,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月11日金城医药发布公告称招商证券许菲菲 周铮 沈敏迪于2024年6月11日调研我司。金城医药是国内第一家启动虾青素产品转基因安全评价的企业,已获得转基因生物安全审批书并开展相应的试验工作。金城医药2024年一季报显示,公司主营收入9.32亿元,同比上升12.32%;归母净利润8297.13万元,同比上升65.43%;扣非净利润8031.36万元,同比上升87.19%;负债率35.28%,投资收益-16.43万元,财务费用-54.16万元,毛利率44.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061200000144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","06099","600999","BK0028","BK0183","300233","BK1564","BK1147","BK0239","BK0010","BK0188","BK0012"],"gpt_icon":0},{"id":"2441070937","title":"金城医药:目前尚未上市销售,公司将根据市场及客户需求安排销售事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2441070937","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441070937?lang=zh_cn&edition=full","pubTime":"2024-06-08 23:00","pubTimestamp":1717858832,"startTime":"0","endTime":"0","summary":"金城医药董秘:投资者,您好,公司暂不涉及细胞治疗领域相关业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060800015479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2441658067","title":"金城医药:具体服用请按照说明书用法用量或寻求专业人士指导","url":"https://stock-news.laohu8.com/highlight/detail?id=2441658067","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441658067?lang=zh_cn&edition=full","pubTime":"2024-06-07 23:00","pubTimestamp":1717772438,"startTime":"0","endTime":"0","summary":"金城医药董秘:投资者,您好,产品利润受多种因素影响,公司将通过多种措施提高生产效率,提升生产技术、优化流程以有效降低生产成本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700050959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2441006564","title":"金城医药:截至2024年5月底,公司股东户数为29,813户","url":"https://stock-news.laohu8.com/highlight/detail?id=2441006564","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441006564?lang=zh_cn&edition=full","pubTime":"2024-06-07 21:02","pubTimestamp":1717765356,"startTime":"0","endTime":"0","summary":"证券之星消息,金城医药06月07日在投资者关系平台上答复投资者关心的问题。投资者:请问截止至2024年5月20日公司股东人数总数是多少?金城医药董秘:投资者,您好,截至2024年5月底公司股东户数为29,813户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700046524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2435678192","title":"金城医药最新公告:头孢羟氨苄干混悬剂增加规格取得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435678192","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435678192?lang=zh_cn&edition=full","pubTime":"2024-05-16 18:31","pubTimestamp":1715855489,"startTime":"0","endTime":"0","summary":"金城医药公告,全资子公司上海金城素智药业有限公司收到国家药监局下发的头孢羟氨苄干混悬剂《药品补充申请批准通知书》。同意该品增加规格。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600028446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2435687513","title":"金城医药(300233.SZ)子公司收到氯诺昔康化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2435687513","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435687513?lang=zh_cn&edition=full","pubTime":"2024-05-14 20:59","pubTimestamp":1715691573,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金城医药(300233.SZ)公告,公司全资子公司北京金城泰尔制药有限公司(简称“金城泰尔”)收到国家药监局下发的化学原料药上市申请批准通知书,相关化学原料药名称为:氯诺昔康。氯诺昔康一种非甾体抗炎药,具有较强的镇痛和解热作用。它主要通过抑制环氧化酶(COX)来减少前列腺素的合成,从而发挥药效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2435976065","title":"金城医药最新公告:氯诺昔康收到化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435976065","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435976065?lang=zh_cn&edition=full","pubTime":"2024-05-14 20:00","pubTimestamp":1715688023,"startTime":"0","endTime":"0","summary":"金城医药公告,子公司金城泰尔收到化学原料药上市申请批准通知书,化学原料药名称为氯诺昔康,具有较强的镇痛和解热作用。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400030730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2434404805","title":"金城医药:公司拥有生物合成的研发及产业化平台,具备从研发到中试再到产业化落地的产业链平台优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2434404805","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434404805?lang=zh_cn&edition=full","pubTime":"2024-05-10 01:02","pubTimestamp":1715274126,"startTime":"0","endTime":"0","summary":"公司将持续加大研发投入,形成更具竞争力的产业链及平台优势,推动公司向更高质量发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000000248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2433637467","title":"金城医药(300233)5月7日主力资金净卖出66.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433637467","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433637467?lang=zh_cn&edition=full","pubTime":"2024-05-08 09:20","pubTimestamp":1715131245,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月7日收盘,金城医药报收于19.05元,下跌2.06%,换手率7.51%,成交量27.8万手,成交额5.25亿元。近5日资金流向一览见下表:金城医药融资融券信息显示,融资方面,当日融资买入7610.47万元,融资偿还5317.17万元,融资净买入2293.3万元,连续3日净买入累计8994.47万元。金城医药主营业务:涵盖医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800014074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2433110495","title":"顶层文件出台在即!合成生物概念异军突起,产业发展步伐加快","url":"https://stock-news.laohu8.com/highlight/detail?id=2433110495","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433110495?lang=zh_cn&edition=full","pubTime":"2024-05-06 11:27","pubTimestamp":1714966042,"startTime":"0","endTime":"0","summary":"万亿赛道","market":"us","thumbnail":"https://img3.gelonghui.com/3f4af-68068c54-1f5a-4b4e-8af1-306881282c33.jpg?guru_height=718&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3f4af-68068c54-1f5a-4b4e-8af1-306881282c33.jpg?guru_height=718&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/726553","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["603739","300233","BK0188","BK0046","BK0070","BK0239","BK0168","BK0028","BK0226","BK0238","301258","BK0077","300381","301301","600789","001366"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0895},{"period":"3month","weight":-0.0532},{"period":"6month","weight":-0.0143},{"period":"1year","weight":-0.25},{"period":"ytd","weight":-0.1356}],"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","perCapita":"13057股","boardName":"医药制造业","registeredCapital":"38387万元","compareEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0461},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":-0.0041}],"survey":" 山东金城医药集团股份有限公司主要从事医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。主要产品包括AE活性酯、头孢他啶活性酯、呋喃铵盐、头孢克肟活性酯、头孢地尼活性酯以及三嗪环、头孢唑林钠、头孢曲松钠、头孢他啶、头孢噻肟、头孢硫脒、谷胱甘肽、腺苷蛋氨酸、硝呋太尔制霉素阴道软胶囊、硝呋太尔胶囊、富马酸比索洛尔胶囊、氯喹那多普罗雌烯阴道片等。公司坚持医药化工和特色原料药的发展方向,经过十多年的发展,已经成为全国最大的头孢类医药中间体生产企业。","serverTime":1721237164060,"listedPrice":18.6,"stockholders":"28351人(较上一季度减少4.90%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}